New drug XTX301 takes on advanced cancers in first human trial

NCT ID NCT05684965

Recruiting now Disease control Sponsor: Xilio Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XTX301
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early, first-in-human trial, so safety and effectiveness are not yet known. Many drug candidates fail in early testing, and benefits may be limited to certain tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma cervical cancer colorectal cancer endometrial cancer endometrial carcinoma head and neck squamous cell carcinoma hormone-resistant prostate carcinoma melanoma neoplasm non-small cell lung carcinoma ovarian cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Locations

Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
HealthPartners Frauenshuh Cancer center
RECRUITING

Saint Louis Park, Minnesota, 55426, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Sheboygan Cancer & Blood Specialists
WITHDRAWN

Sheboygan, Wisconsin, 53081, United States
The Gabrail Pharmacology Phase 1 Research Center
RECRUITING

Canton, Ohio, 44718, United States
The Ohio State University Wexner Medical Center
RECRUITING

Columbus, Ohio, 43221, United States
Tranquil Clinical Research
COMPLETED

Webster, Texas, 77598, United States
University Hospital Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States
University of California, Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States

Contact Email: •••••@•••••
University of Pittsburgh Medical Center-Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.